Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies

Jp, Armand; Cunningham, David; E, van Cutsem; Jl, Misset; Ch, Köhne

doi:10.1097/00001813-199911001-00002

Cited by 8 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With single-agent irinotecan, RRs in gastric cancer are approximately 20% [26][27][28]. In combination with cisplatin, 5-FU, or mitomycin, RRs of up to 51% and median survival of up to 10.7 months have been reported in randomized phase II studies [29][30][31][32][33][34].…”

Section: Chemotherapy In Advanced Gastric Cancermentioning

confidence: 99%

The role of chemotherapy in the current treatment of gastric cancer

Cutsem

Ohtsu

2002

Gastric Cancer

View full text Add to dashboard Cite

Section: Chemotherapy In Advanced Gastric Cancermentioning

confidence: 99%

The role of chemotherapy in the current treatment of gastric cancer

Cutsem

Ohtsu

2002

Gastric Cancer

View full text Add to dashboard Cite

“…Irinotecan (CPT-11), a camptothecin analog, has shown promising single-agent activity in patients with AGC with response rates of 14-23% in phase II trials [14][15][16][17] . Combinations of irinotecan with 5-FU and LV have also shown an obvious synergistic activity in initial trials testing the effi cacy of such combinations in the treatment of AGC.…”

Section: Introductionmentioning

confidence: 99%

Irinotecan Combined with Infusional 5-Fluorouracil and High-Dose Leucovorin for the Treatment of Advanced Gastric Carcinoma as the First-Line Chemotherapy

Yılmaz¹,

Öztop²,

Alacacıoğlu³

et al. 2006

Chemotherapy

View full text Add to dashboard Cite

Background: Because of insufficient activity and high toxicity of current chemotherapy regimens in advanced gastric cancer (AGC), there is a need for newer regimens. Methods: Twenty-five chemonaive patients with AGC have been treated with FOLFIRI regimen consisting of irinotecan 180 mg/m² over 30 min on day 1 combined with leucovorin 200 mg/m² over 2 h followed by 5-fluorouracil 400 mg/m² as bolus and 600 mg/m² as a 22-hour infusion on day 1 and 2. The treatment was administered every 14th day until progression or intolerable toxicity. Results: Twenty-five patients (17 male, 8 female; 22 patients with PS 0–1 and 3 patients with PS 2), median age 54 (range 25–77), received a total of 230 courses of chemotherapy (median 9; range 1–18). Objective responses were observed in 9 patients (36%), all being partial. Median progression-free survival, 1- and 2-year progression-free survival rates were 8.6 months, 28.4% and 15.3%, respectively. Median overall survival, 1- and 2-year overall survival rates were 11.6 months, 48.0% and 17.8%, respectively. As serious adverse events, grade 3–4 neutropenia was observed in 5 patients (20.0%), grade 3 diarrhea in 4 patients (16.0%). No treatment-related death occurred. Conclusion: FOLFIRI regimen is an active regimen with acceptable toxicity for the treatment of AGC.

show abstract

“…DNA topoisomerase I, which makes singlestranded nicks in DNA that cause the helix to relax and avoid overcoiling, is a candidate target for anticancer drugs [82]. DNA topoisomerase I can be inhibited by quercetin, acacetin, apigenin, kaempferol and morin [83] by a mechanism involving the inhibition of topoisomerase I-catalyzed DNA religation of the DNA strands.…”

Section: Inhibition Of Dna Topoisomerase Activitymentioning

confidence: 99%

Phytoestrogens: Perpetrators Or Protectors?

2007

View full text Add to dashboard Cite

Phytoestrogens are estrogen-like substances produced by plants that account for some of the constituents present in vegetation that may be responsible for the health benefits of a diet rich in fruit and vegetables. Phytoestrogens have a plethora of different actions that they are capable of exerting on cellular metabolism. This review will focus on some of the major non-estrogen receptor-mediated cellular effects used by phytoestrogens and will draw attention to the fact that while they may have a number of beneficial effects, particularly in offering a protective effect against some hormone-dependent cancers, such as breast and prostate cancer, they may also have possible unfavorable effects by interfering with the functioning of normal cellular activities such as receptor-mediated signal transduction and DNA replication, as well as being genotoxic, mutagenic and promoting the proliferation of some cancer cells.

show abstract

Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies

Cited by 8 publications

References 0 publications

The role of chemotherapy in the current treatment of gastric cancer

The role of chemotherapy in the current treatment of gastric cancer

Irinotecan Combined with Infusional 5-Fluorouracil and High-Dose Leucovorin for the Treatment of Advanced Gastric Carcinoma as the First-Line Chemotherapy

Phytoestrogens: Perpetrators Or Protectors?

Contact Info

Product

Resources

About